Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 183 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2016', provides an overview of the Cytomegalovirus (HHV-5) Infections pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Cytomegalovirus (HHV-5) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cytomegalovirus (HHV-5) Infections and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections
- The report reviews pipeline therapeutics for Cytomegalovirus (HHV-5) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Cytomegalovirus (HHV-5) Infections therapeutics and enlists all their major and minor projects
- The report assesses Cytomegalovirus (HHV-5) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Cytomegalovirus (HHV-5) Infections

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Cytomegalovirus (HHV-5) Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Cytomegalovirus (HHV-5) Infections Overview 10
Therapeutics Development 11
Pipeline Products for Cytomegalovirus (HHV-5) Infections - Overview 11
Pipeline Products for Cytomegalovirus (HHV-5) Infections - Comparative Analysis 12
Cytomegalovirus (HHV-5) Infections - Therapeutics under Development by Companies 13
Cytomegalovirus (HHV-5) Infections - Therapeutics under Investigation by Universities/Institutes 15
Cytomegalovirus (HHV-5) Infections - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Cytomegalovirus (HHV-5) Infections - Products under Development by Companies 20
Cytomegalovirus (HHV-5) Infections - Products under Investigation by Universities/Institutes 23
Cytomegalovirus (HHV-5) Infections - Companies Involved in Therapeutics Development 24
Adicet Bio, Inc. 24
AIMM Therapeutics B.V. 25
Altor BioScience Corporation 26
Astellas Pharma Inc. 27
Atara Biotherapeutics, Inc. 28
Bionor Pharma ASA 29
Biotest AG 30
Cell Medica Limited 31
Chimerix, Inc. 32
China Biologic Products, Inc. 33
CyTuVax B.V. 34
Fate Therapeutics, Inc. 35
GlaxoSmithKline Plc 36
Hookipa Biotech AG 37
Humabs BioMed SA 38
Kadmon Corporation, LLC 39
Laboratoires Thea S.A. 40
Merck & Co., Inc. 41
Microbiotix, Inc. 42
Novartis AG 43
Pfizer Inc. 44
Phoenix Biotechnology, Inc. 45
Savoy Pharmaceuticals, Inc. 46
Sigma-Tau S.p.A. 47
Trellis Bioscience, Inc. 48
Vakzine Projekt Management GmbH 49
VBI Vaccines Inc. 50
Vical Incorporated 51
Cytomegalovirus (HHV-5) Infections - Therapeutics Assessment 52
Assessment by Monotherapy Products 52
Assessment by Combination Products 53
Assessment by Target 54
Assessment by Mechanism of Action 56
Assessment by Route of Administration 58
Assessment by Molecule Type 60
Drug Profiles 62
AIC-387 - Drug Profile 62
AIC-476 - Drug Profile 63
AIC-813 - Drug Profile 64
AL-18 - Drug Profile 65
Antibodies to Inhibit HLA-A2 for Cytomegalovirus Infections - Drug Profile 66
Antibody for Human Cytomegalovirus Infection - Drug Profile 67
Antiviral TCR-Ck - Drug Profile 68
Antiviral TCR-Ig - Drug Profile 69
ASP-0113 - Drug Profile 70
brincidofovir - Drug Profile 71
BT-084 - Drug Profile 74
Cell Therapy 3 For CMV - Drug Profile 75
Cell Therapy for Cytomegalovirus Infections - Drug Profile 76
Cellular Immunotherapy for CMV Infections - Drug Profile 77
Cellular Immunotherapy for Cytomegalovirus and Adenovirus Infections - Drug Profile 78
Cellular Immunotherapy for Cytomegalovirus Infections - Drug Profile 79
Cellular Immunotherapy for Cytomegalovirus Infections - Drug Profile 80
Cellular Immunotherapy for Cytomegalovirus Infections - Drug Profile 81
Cellular Immunotherapy for Cytomegalovirus Infections and GBM - Drug Profile 82
Cellular Immunotherapy for Infectious Disease - Drug Profile 83
Cellular Immunotherapy for Infectious Diseases - Drug Profile 84
Cellular Immunotherapy for Viral Infections - Drug Profile 85
Cellular Immunotherapy for Viral Infections Post-HSCT - Drug Profile 86
Cellular Immunotherapy to Target CMV Antigen for Cytomegalovirus Infections - Drug Profile 87
Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile 88
Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile 90
CMX-669 - Drug Profile 91
CSJ-148 - Drug Profile 92
CyMVectin - Drug Profile 93
cytomegalovirus (virus like particle) vaccine - Drug Profile 94
Cytomegalovirus vaccine - Drug Profile 95
Cytomegalovirus vaccine - Drug Profile 96
Cytomegalovirus vaccine - Drug Profile 98
Cytomegalovirus vaccine 1 - Drug Profile 99
Cytomegalovirus vaccine 2 - Drug Profile 101
Cytovir-CMV - Drug Profile 102
filociclovir - Drug Profile 104
ganciclovir - Drug Profile 106
Gene Therapy for Cytomegalovirus Infections - Drug Profile 107
HB-101 - Drug Profile 108
letermovir - Drug Profile 109
maribavir - Drug Profile 110
MBX-2168 - Drug Profile 112
Monoclonal Antibody for Cytomegalovirus Infections - Drug Profile 113
Monoclonal Antibody for HCMV Infections - Drug Profile 114
Monoclonal Antibody to Agonize LTbR for CMV Infection - Drug Profile 115
Peptides to Inhibit Heparan Sulfate for HHV-5 Infections - Drug Profile 117
ProTmune - Drug Profile 118
PTX-3 - Drug Profile 119
RBT-301 - Drug Profile 120
Recombinant Peptide for Infectious Diseases - Drug Profile 121
RKP-00156 - Drug Profile 122
Small Molecule for Cytomegalovirus - Drug Profile 123
Small Molecules for CMV Infections - Drug Profile 124
Small Molecules for CMV infections and Cancer - Drug Profile 125
Small Molecules to Activate Sirtuin for Viral Infections - Drug Profile 126
Small Molecules to Inhibit Acetyl-CoA Carboxylase for CMV Infections - Drug Profile 127
Small Molecules to Inhibit Cyclin-Dependent Kinase 7 for Oncology, Inflammation and Infectious Diseases - Drug Profile 128
Small Molecules to Inhibit Na+/K+ ATPase for Human Cytomegalovirus Infections - Drug Profile 129
TRL-345 - Drug Profile 130
V-160 - Drug Profile 131
Vacc-CMV - Drug Profile 132
Vaccine for Cytomegalovirus Infection and Glioblastoma Multiforme - Drug Profile 133
VBI-1501A - Drug Profile 134
Viralym-C - Drug Profile 135
Viroprev - Drug Profile 136
VPM-2001 - Drug Profile 137
Cytomegalovirus (HHV-5) Infections - Recent Pipeline Updates 138
Cytomegalovirus (HHV-5) Infections - Dormant Projects 161
Cytomegalovirus (HHV-5) Infections - Discontinued Products 166
Cytomegalovirus (HHV-5) Infections - Product Development Milestones 167
Featured News & Press Releases 167
Appendix 178
Methodology 178
Coverage 178
Secondary Research 178
Primary Research 178
Expert Panel Validation 178
Contact Us 178
Disclaimer 179

List of Tables

Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H1 2016 15
Number of Products under Development for Cytomegalovirus (HHV-5) Infections - Comparative Analysis, H1 2016 16
Number of Products under Development by Companies, H1 2016 17
Number of Products under Development by Companies, H1 2016 (Contd..1) 18
Number of Products under Investigation by Universities/Institutes, H1 2016 19
Comparative Analysis by Late Stage Development, H1 2016 20
Comparative Analysis by Clinical Stage Development, H1 2016 21
Comparative Analysis by Early Stage Development, H1 2016 22
Comparative Analysis by Unknown Stage Development, H1 2016 23
Products under Development by Companies, H1 2016 24
Products under Development by Companies, H1 2016 (Contd..1) 25
Products under Development by Companies, H1 2016 (Contd..2) 26
Products under Investigation by Universities/Institutes, H1 2016 27
Cytomegalovirus (HHV-5) Infections - Pipeline by Adicet Bio, Inc., H1 2016 28
Cytomegalovirus (HHV-5) Infections - Pipeline by AIMM Therapeutics B.V., H1 2016 29
Cytomegalovirus (HHV-5) Infections - Pipeline by Altor BioScience Corporation, H1 2016 30
Cytomegalovirus (HHV-5) Infections - Pipeline by Astellas Pharma Inc., H1 2016 31
Cytomegalovirus (HHV-5) Infections - Pipeline by Atara Biotherapeutics, Inc., H1 2016 32
Cytomegalovirus (HHV-5) Infections - Pipeline by Bionor Pharma ASA, H1 2016 33
Cytomegalovirus (HHV-5) Infections - Pipeline by Biotest AG, H1 2016 34
Cytomegalovirus (HHV-5) Infections - Pipeline by Cell Medica Limited, H1 2016 35
Cytomegalovirus (HHV-5) Infections - Pipeline by Chimerix, Inc., H1 2016 36
Cytomegalovirus (HHV-5) Infections - Pipeline by China Biologic Products, Inc., H1 2016 37
Cytomegalovirus (HHV-5) Infections - Pipeline by CyTuVax B.V., H1 2016 38
Cytomegalovirus (HHV-5) Infections - Pipeline by Fate Therapeutics, Inc., H1 2016 39
Cytomegalovirus (HHV-5) Infections - Pipeline by GlaxoSmithKline Plc, H1 2016 40
Cytomegalovirus (HHV-5) Infections - Pipeline by Hookipa Biotech AG, H1 2016 41
Cytomegalovirus (HHV-5) Infections - Pipeline by Humabs BioMed SA, H1 2016 42
Cytomegalovirus (HHV-5) Infections - Pipeline by Kadmon Corporation, LLC, H1 2016 43
Cytomegalovirus (HHV-5) Infections - Pipeline by Laboratoires Thea S.A., H1 2016 44
Cytomegalovirus (HHV-5) Infections - Pipeline by Merck & Co., Inc., H1 2016 45
Cytomegalovirus (HHV-5) Infections - Pipeline by Microbiotix, Inc., H1 2016 46
Cytomegalovirus (HHV-5) Infections - Pipeline by Novartis AG, H1 2016 47
Cytomegalovirus (HHV-5) Infections - Pipeline by Pfizer Inc., H1 2016 48
Cytomegalovirus (HHV-5) Infections - Pipeline by Phoenix Biotechnology, Inc., H1 2016 49
Cytomegalovirus (HHV-5) Infections - Pipeline by Savoy Pharmaceuticals, Inc., H1 2016 50
Cytomegalovirus (HHV-5) Infections - Pipeline by Sigma-Tau S.p.A., H1 2016 51
Cytomegalovirus (HHV-5) Infections - Pipeline by Trellis Bioscience, Inc., H1 2016 52
Cytomegalovirus (HHV-5) Infections - Pipeline by Vakzine Projekt Management GmbH, H1 2016 53
Cytomegalovirus (HHV-5) Infections - Pipeline by VBI Vaccines Inc., H1 2016 54
Cytomegalovirus (HHV-5) Infections - Pipeline by Vical Incorporated, H1 2016 55
Assessment by Monotherapy Products, H1 2016 56
Assessment by Combination Products, H1 2016 57
Number of Products by Stage and Target, H1 2016 59
Number of Products by Stage and Mechanism of Action, H1 2016 61
Number of Products by Stage and Route of Administration, H1 2016 63
Number of Products by Stage and Molecule Type, H1 2016 65
Cytomegalovirus (HHV-5) Infections Therapeutics - Recent Pipeline Updates, H1 2016 142
Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2016 165
Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..1), H1 2016 166
Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..2), H1 2016 167
Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..3), H1 2016 168
Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..4), H1 2016 169
Cytomegalovirus (HHV-5) Infections - Discontinued Products, H1 2016 170